Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angeliq for Blood Pressure in Postmenopausal Women
NCT00102141Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of estradiol + drospirenone in hypertension (HTN) (5 arms), sponsored by Bayer. Primary endpoints: Mean change in systolic office blood pressure at 8 weeks and Mean change in 24-hour systolic ambulatory blood pressure measurement at 8 weeks. Started Apr 2004; status: completed.
02
Drugs
estradiol + drospirenone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00102141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00102141.